Stellantis Joins GlobalPlatform to Advance Global Automotive Cybersecurity Standards
4.9.2025 15:00:00 CEST | Business Wire | Press release
Stellantis is the latest major auto OEM to join GlobalPlatform, helping to accelerate cross-industry collaboration on cybersecurity standardization for software-defined vehicles (SDVs).
Stellantis—the company behind 14 major auto brands, including Alfa Romeo, Chrysler, FIAT, Jeep®, Opel, Peugeot, and Vauxhall—has joined GlobalPlatform to help align its technologies with evolving automotive use cases and regulatory requirements. As part of the agreement, Bill Mazzara, North American Regulatory Lead and Technical Fellow for Product Cybersecurity at Stellantis, becomes co-chair of the GlobalPlatform Automotive Task Force.
Stellantis joins a growing community of automakers, cybersecurity firms, silicon vendors, and academic institutions in GlobalPlatform that are advancing a standardized approach to meeting the complex cybersecurity demands of today’s SDVs. Recent members of the Automotive Task Force include AIST, Cariad (Volkswagen), Dekra, ETAS, Linaro, Rambus, Renesas, Stellantis, Uni-sentry, and Woven by Toyota.
“GlobalPlatform’s Automotive Task Force is helping the industry converge on a platform of secure, scalable foundations for software-defined vehicles,” said Bill Mazzara. “Our engagement is focused on harmonizing security standards and fostering cross-industry collaboration to meet evolving regulatory and operational requirements and ultimately our customers' expectations.”
The Automotive Task Force is at the forefront of bringing market-proven GlobalPlatform technologies and specifications to the automotive sector. It recently reached a major milestone by fully aligning these specifications with the new addendum of the SAE J3101 Hardware Protected Security Environment automotive cybersecurity standard (J3101-5). This creates the formal means for GlobalPlatform-compliant suppliers to demonstrate automatic compliance with J3101. It provides automakers with confidence that components embedded in their vehicles meet cybersecurity requirements and facilitate integration with applications of AutoSAR, Car Connectivity Consortium, and other automotive frameworks.
The Automotive Task Force has also developed a protection profile based on the SESIP evaluation methodology to ensure component-level certifications are aligned with SAE J3101. This allows certified components to be reused across platforms without the need for re-evaluation, saving time and resources across the supply chain.
“Stellantis’ participation in GlobalPlatform reflects our commitment to advancing standardized, secure technologies that can scale across the automotive ecosystem,” said Muttalip Akin, SVP, Head of Electrical, Electronic & Hardware Engineering, Stellantis.
“These recent advancements represent a breakthrough in the industry’s goal of creating a standardized and certified platform for secure vehicle applications,” said Ana Tavares Lattibeaudiere, Executive Director, GlobalPlatform. “We urge further companies from across the auto industry to join us in our mission to lower risk, reduce costs, and eliminate fragmentation across the automotive cybersecurity ecosystem.”
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828443903/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom